StockData
Novartis AG logo

Novartis AG (NVS) stock

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$161.52+0.73 (+0.45%)

Close on Nov 2, 2026Market cap $308.20BP/E 22.6Yield –

Earnings

Novartis's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Novartis's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Novartis has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Novartis puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Novartis filed with the SEC as exhibits to Form 8-K or 6-K

  1. 6-K
  2. 6-K
  3. 6-K
  4. 6-K
  5. 6-K
  6. 6-K
  7. 6-K
  8. 6-K
  9. 6-K
  10. 6-K
  11. 6-K
  12. 6-K
  13. 6-K
  14. 6-K
  15. 6-K